IDDA.F INNATE PHARMA SP.ADR/1

Healthcare Biotechnology Frankfurt Exchange
1.19 EUR
Close of Nov 12, 2026
0.9300 2.18
Market cap
EUR 133M
P/E
-
P/B
32.25x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is IDDA.F undervalued?

Graham number

The Graham number of INNATE PHARMA SP.ADR/1 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

INNATE PHARMA SP.ADR/1 fundamental analysis

No fundamental analysis for INNATE PHARMA SP.ADR/1 yet.

INNATE PHARMA SP.ADR/1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About INNATE PHARMA SP.ADR/1

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that…

Full company profile